Hidenori Takahashi

Osaka University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (21)

Year:

2026

Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone (Gem‐RT) in BR‐PC. Methods Of 201 patients with BR‐PC enrolled in the study, 102 were receiving GnP‐RT and 99 were receiving Gem‐RT. We evaluated clinical outcomes between these two groups, including CA19‐9 values, rate of tumor reduction, overall (OS) and progression‐free survival (PFS) rates, and distant and local recurrence. Results CA19‐9 values and tumor size reduction rate after NACRT were significantly higher with GnP‐RT than with Gem‐RT. With GnP‐RT, the 5‐year OS rate was 55.2% and the PFS rate was 42.1%, both significantly better than rates with Gem‐RT (OS, 35.4%, p = 0.006; PFS, 31.9%, p = 0.041). The incidence of distant recurrence with GnP‐RT was significantly lower than with Gem‐RT ( p = 0.018), but the incidence of local recurrence did not differ between the two groups ( p = 0.905), indicating that the better survival with GnP‐RT might arise from a systemic effect of enhanced chemotherapy. Conclusion Enhanced chemotherapy may improve survival in patients with BR‐PC by suppressing distant metastasis through a potent systemic antitumor effect.

Year:

2026

Background: Preoperative chemotherapy is increasingly used for colorectal liver metastases (CRLM), but simple risk stratification tools for routine practice remain limited. We developed a simple risk model to predict outcomes after curative-intent CRLM resection, including in patients receiving preoperative chemotherapy. Methods: We retrospectively analyzed 115 patients who underwent initial curative-intent liver resection for CRLM at two centers. Factors associated with recurrence-free survival (RFS) and overall survival (OS) were evaluated using Cox proportional hazards models and log-rank tests. Model performance was benchmarked against the Beppu nomogram and Fong’s clinical risk score using the area under the curve (AUC). Outcomes were also assessed based on response to preoperative chemotherapy. Results: Having ≥3 CRLMs was the only independent predictor common to both OS and RFS. Among patients with 1–2 CRLMs, the largest tumor diameter being ≥5 cm independently predicted RFS. A composite high-risk definition (≥3 CRLMs, or 1–2 CRLMs with a diameter ≥ 5 cm) independently predicted recurrence (HR 2.05, p = 0.007) and overall mortality (HR 2.24, p = 0.017). The AUCs were similar to the Beppu nomogram for recurrence (0.68 vs. 0.70 (p = 0.683) at 36 months, 0.66 vs. 0.68 (p = 0.766) at 60 months) and to Fong’s score for survival (0.59 vs. 0.64 (p = 0.430) at 36 months, 0.65 vs. 0.74 (p = 0.074) at 60 months). Among patients receiving preoperative chemotherapy (n = 72), high-risk status was associated with poorer RFS (HR 3.11, p < 0.001) and OS (HR 2.80, p = 0.010). Within this subgroup, progressive disease (PD) was associated with worse outcomes than disease control (CR/PR/SD). Conclusions: This two-variable, rule-based model provides an easy-to-use tool for postoperative risk stratification after CRLM resection, and incorporating chemotherapy response may further refine prognostication.

Year:

2026

Year:

2025

Aim Appropriate reassessment of treatment response plays a crucial role in identifying optimal candidates for resection in neoadjuvant treatment (NAT) strategy for pancreatic cancer (PC); however, radiological evaluations are associated with limitations such as discrepancies with pathological response. Radiotherapy can induce inflammatory responses, potentially leading to an overestimation of residual tumor viability. This study explored the relationship between radiographic and pathological response assessments in NAT, focusing on the difference between neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT). Methods Patients with resectable, borderline resectable, and initially unresectable locally advanced PC who had undergone curative resection after NAT were included in this study. The correlation between radiological assessment using RECIST criteria and pathological response according to Evans classification in the NAC and NACRT groups was assessed. Results No significant differences were observed between the groups in terms of the findings of the RECIST assessment; however, the rate of favorable pathologic response (Evans ≥ IIb) in the NACRT group was significantly higher ( p < 0.001). Furthermore, a comparison between the Evans grade for each RECIST criteria revealed a higher favorable pathologic response rate in the NACRT group among patients categorized as “stable disease (SD)” ( p < 0.001). Some patients receiving NACRT who were initially classified as SD exhibited pathological complete response (Evans IV). Conclusions Discrepancies between radiographic and pathological response assessments in NAT for PC may differ between NAC and NACRT. In reassessment after NAT, the specific type of therapy administered, that is, NAC or NACRT, must be considered, especially in cases wherein radiographic alterations are minimal.

Year:

2025

Aim Decreasing intraoperative blood loss is one reported advantage of laparoscopic surgery compared with open surgery. However, several reports indicate that blood loss during laparoscopic surgery may be underestimated. No studies have evaluated this possibility in laparoscopic distal pancreatectomy (LDP). Here we evaluated estimated blood loss (e‐BL) compared to intraoperative blood loss (i‐BL) during distal pancreatectomy (DP). Methods This study included 114 patients undergoing DP in our institution during the study period. We examined the relationship between i‐BL and e‐BL. Based on these results, we further investigated the relationship with LDP. Results The laparoscopic approach was used in a significantly higher percentage of patients in e‐BL > i‐BL group compared to e‐BL i‐BL trend in the LDP group was consistent, regardless of the indication for DP. In contrast, the finding of i‐BL > e‐BL in the ODP group was limited to patients with pancreatic cancer. Conclusion During LDP, e‐BL was significantly more than i‐BL. During ODP, e‐BL was significantly less than i‐BL, only in patients with pancreatic cancer. These results suggested the possibility of i‐BL underestimation during LDP, and overestimation during ODP in cases with pancreatic cancer.

Year:

2025

Introduction We assessed immune-mediated adverse events (imAEs) in the TOPAZ-1 (NCT03875235) study of durvalumab plus gemcitabine and cisplatin (GemCis) in advanced biliary tract cancer (aBTC). Methods Participants were randomized 1:1 to durvalumab (1500 mg) or placebo, plus GemCis (gemcitabine [1000 mg/m2] and cisplatin [25 mg/m2]) intravenously, followed by durvalumab (1500 mg) or placebo Q4W. We assessed imAE incidence, time to onset (TTO), and association with overall survival (OS). Results In durvalumab (n = 338) versus placebo (n = 342), imAEs were reported in 13.9% versus 4.7% of participants, with median TTO of 127.0 versus 86.5 days, respectively. OS HR for durvalumab versus placebo in participants with imAEs was 0.59 (95% CI, 0.30-1.23) and was 0.83 (95% CI, 0.70-1.00) in participants without imAEs. Conclusions Durvalumab demonstrated an OS benefit versus placebo in aBTC, irrespective of imAEs, which were mostly low grade and manageable. The results in these subgroups were consistent with the overall primary analysis. Trial registration ClinicalTrials.gov NCT03875235

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (6)

Daisaku Yamada

Osaka University

JAPAN
View details

Hidetoshi Eguchi

-

JAPAN
View details

Takehiro Noda

Associate Professor

Osaka University

JAPAN
View details

Joon Oh Park

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Shunbun Kita

Associate Professor

Osaka University

JAPAN
View details

Takamichi Ishii

特定准教授 / Program-Specific Associate Professor

Kyoto University

JAPAN
View details